Table 3.

Ongoing clinical trials with treatments combining mTOR inhibitors in MCL.

Registration number	Title	Combination type	Phase
NCT01076543	Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma	Immunomodulatory agent	2, recruiting
NCT01078142	Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell Lymphoma	Chemotherapy and antibody	2, recruiting
NCT00787969	Rituximab, Cladribine, and Temsirolimus in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma	Chemotherapy and antibody	2, recruiting
NCT01389427	Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma	Proteasome inhibitor, antibody and steroid	2, recruiting
NCT01381692	Escalating Doses of Torisel in Combination With Three Chemotherapies Regimens: R-CHOP, R-FC or R-DHA for Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL).	Chemotherapy and antibody	2, not yet recruiting
NCT01281917	Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma	Proteasome inhibitor	2, recruiting